BRIEF—Regeneron's linvoseltamab demonstrates 100% overall response

Regeneron presented its first results from the Phase II LINKER-SMM1 trial evaluating linvoseltamab in high-risk smoldering multiple myeloma (HR-SMM) during an oral plenary presentation at IMS 2025.

Patients with HR-SMM have traditionally undergone observation until progression to multiple myeloma, but early intervention may have the potential to delay or even prevent progression to active disease.

In the study, all efficacy-evaluable patients (received at least one cycle of full-dose 200mg linvoseltamab; n=19), demonstrated exceptional efficacy with a 100% objective response rate.